You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Johnson and Johnson
McKesson
Dow
Express Scripts

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,232,534

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,232,534
Title: Inbred maize line R660H
Abstract:The present invention is drawn to a novel DNA construct comprising an expression cassette having a constitutive promoter which functions in plant cells operably linked to a maize alcohol dehydrogenase intron, a DNA sequence of a gene encoding a Cry 1Ab protein, and a terminator functional in plants and optionally further comprising a second cassette including a promoter which functions in plants operably linked to a maize alcohol dehydrogenase intron, a DNA sequence of a gene encoding for phosphinothricin acetyl transferase, and a terminator functional in plants wherein the two cassettes are transcribed in the same direction. Also provided are transgenic plants, particularly maize plants, having such a construct stably incorporated into their genomes.
Inventor(s): Mettler; Irvin J. (Richmond, CA), Plaisted; Douglas C. (Middleton, ID), Grier; Stephen L. (Stanton, MN), Houghton; Wesley (Naples, FL), Gardiner; Michele (Nampa, ID)
Assignee: Novartis AG (Basel, CH)
Application Number:09/330,737
Patent Claims:1. Seed of maize inbred line R660H having been deposited under ATCC Accession No: 209672, further comprising a nucleic acid construct comprising two cassettes,

wherein the first cassette comprises a CaMV 35S constitutive promoter operably linked to a maize alcohol dehydrogenase intron, a DNA sequence of a gene encoding a Cry1Ab protein, and a terminator functional in plants, and

the second cassette comprises a CaMV 35S promoter which functions in plant cells operably linked to a maize alcohol dehydrogenase intron, a DNA sequence of a gene encoding for phosphinothricin acetyl transferase, and a terminator functional in plants,

wherein the two cassettes are transcribed in the same direction,

wherein the nucleic acid construct is incorporated into the seed's genome on chromosome 8, near position 117, between markers Z1B3 and UMC150a.

2. Seed according to claim 1, wherein the first expression cassette comprises SEQ ID Nos. 1-4 in operable sequence.

3. Seed according to claim 1, wherein the second expression cassette comprises SEQ ID Nos. 5-8 in operable sequence.

4. Seed according to claim 1, wherein the first expression cassette comprises SEQ ID Nos. 1-4 in operable sequence and the second expression cassette comprises SEQ ID Nos. 5-8 in operable sequence.

5. A maize plant, or parts thereof, of inbred line R660H, seed of said line having been deposited under ATCC accession No: 209672, further comprising a nucleic acid construct comprising two cassettes,

wherein the first cassette comprises a CaMV 35S constitutive promoter operably linked to a maize alcohol dehydrogenase intron, a DNA sequence of a gene encoding a Cry1Ab protein, and a terminator functional in plants, and

the second cassette comprises a CaMV 35S promoter which functions in plant cells operably linked to a maize alcohol dehydrogenase intron, a DNA sequence of a gene encoding for phosphinothricin acetyl transferase, and a terminator functional in plants,

wherein the two cassettes are transcribed in the same direction,

wherein the nucleic acid construct is incorporated into the seed's genome on chromosome 8, near position 117, between markers Z1B3 and UMC150a.

6. A maize plant according to claim 5, wherein the first expression cassette comprises SEQ ID Nos. 1-4 in operable sequence.

7. A maize plant according to claim 5, wherein the second expression cassette comprises SEQ ID Nos. 5-8 in operable sequence.

8. A maize plant according to claim 5, wherein the first expression cassette comprises SEQ ID Nos. 1-4 in operable sequence and the second expression cassette comprises SEQ ID Nos. 5-8 in operable sequence.

9. Pollen of the plant of claim 5.

10. An ovule of the plant of claim 5.

11. A maize plant, or parts thereof, having all the genotypic and phenotypic characteristics of a plant according to claim 5.

12. Hybrid maize seed produced by crossing a plant according to claim 5 with an inbred maize plant having a different genotype.

13. Hybrid maize plant produced by growing hybrid maize seed of claim 12.

14. A method of producing hybrid maize seeds comprising the following steps:

(a) planting seeds of a first inbred maize line according to claim 1 and seeds of a second inbred line having a different genotype;

(b) cultivating maize plants resulting from said planting until time of flowering;

(c) emasculating said flowers of plants of one of the maize inbred lines;

(d) allowing pollination of the other inbred line to occur, and

(e) harvesting the hybrid seed produced thereby.

15. Hybrids seed produced by the method of claim 14.

16. Hybrid maize plant produced by growing hybrid maize seed of claim 15.

Details for Patent 6,232,534

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Novartis AG (Basel, CH) 2017-03-14 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Novartis AG (Basel, CH) 2017-03-14 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Novartis AG (Basel, CH) 2017-03-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 6,232,534

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKinsey
Moodys
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.